USPTO Examiner FISCHER JOSEPH - Art Unit 1658

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19173198INTERLEUKIN-15 SUPERAGONIST N-803 IN PEOPLE EXPERIENCING LONG COVIDApril 2025February 2026Abandon1010YesNo
18602255GLP-1/GIP DUAL AGONIST, PREPARATION METHOD AND USE THEREOFMarch 2024July 2025Allow1611YesNo
18600947EGG WHITE PROTEIN ANTI-INFLAMMATORY PEPTIDE AND APPLICATION THEREOFMarch 2024October 2024Allow711YesNo
18581115STAPLED ANTIMICROBIAL PEPTIDEFebruary 2024November 2024Allow901YesNo
18540219GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USEDecember 2023November 2024Allow1112YesNo
18512512AMYLIN RECEPTOR AGONISTSNovember 2023August 2024Allow901NoNo
18492058INSECT NEUROPEPTIDES 4October 2023March 2025Allow1721YesNo
18492006INSECT NEUROPEPTIDES 3October 2023September 2024Allow1111NoNo
18375639CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPYOctober 2023December 2024Abandon1410NoNo
18468535MODIFIED PLASMA CLOTTING FACTOR VIII AND METHOD OF USE THEREOFSeptember 2023January 2026Allow2911YesNo
18303093CARDIAC-SPECIFIC TARGETING-PEPTIDE (CTP), COMPOSITIONS, AND USES THEREOFApril 2023February 2026Allow3420YesNo
18003572HUMAN IL23 RECEPTOR BINDING POLYPEPTIDESDecember 2022March 2026Abandon3901NoNo
18079099REGULATORY T CELL EPITOPESDecember 2022September 2024Abandon2101NoNo
17881605ULTRASOUND-ASSISTED SIMULATED DIGESTION METHOD OF CASEIN ACTIVE PEPTIDE AND APPLICATION THERE OF IN HEALTH FOODSAugust 2022November 2024Abandon2801NoNo
17792591TARGETING PAR1 AND PAR2 TO REGULATE LIPID AND CHOLESTEROL ABUNDANCEJuly 2022November 2025Abandon4001NoNo
17863319PHARMACEUTICAL COMPOSITIONJuly 2022February 2025Abandon3111NoNo
17824256TREATMENT AND PREVENTION OF OSTEOPOROSIS IN HIGH BODY MASS INDEX INDIVIDUALSMay 2022June 2024Abandon2511NoNo
17778759BIOTIN MOIETY-CONJUGATED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING THE SAMEMay 2022January 2026Abandon4401NoNo
17742640COMPOUNDS AND METHODS FOR INHIBITING PROTOZOAN PARASITESMay 2022May 2025Allow3620NoNo
17692471COMPOSITIONS COMPRISING PEPTIDES COMPRISING VARIANT KINESIN LIGHT CHAIN 1 AND CELL-PENETRATING PEPTIDESMarch 2022October 2024Allow3110NoNo
17574947METHODS AND COMPOSITIONS FOR NONINVASIVE DETECTION OF ORGAN TRANSPLANT REJECTIONJanuary 2022December 2025Allow4751YesNo
17562014POLYPEPTIDE CONJUGATES AND METHODS OF USESDecember 2021September 2022Allow811YesNo
17557343BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCEDecember 2021May 2025Abandon4130NoNo
17551701POLYPEPTIDES AND USES THEREOFDecember 2021February 2025Abandon3801YesNo
17526203STABILIZED AFGF COMPOSITIONSNovember 2021September 2024Abandon3421NoNo
17525354HEPARIN-BINDING CATIONIC PEPTIDE SELF-ASSEMBLING PEPTIDE AMPHIPHILES USEFUL AGAINST DRUG-RESISTANT BACTERIANovember 2021February 2025Allow3911NoNo
17521366METHODS FOR TREATING SYMPTOMS OF DRY EYE DISEASENovember 2021March 2024Allow2910YesNo
17593512A STABLE PARENTERAL DOSAGE FORM OF CETRORELIX ACETATESeptember 2021January 2026Abandon5221NoNo
17438646SINGLE CHAIN FACTOR VIII MOLECULESeptember 2021November 2025Abandon5021NoNo
17431867PAR4 DERIVED PEPTIDES, ANALOGS AND USES THEREOFAugust 2021November 2024Abandon3901NoNo
17430365POLYPEPTIDES FOR RESTORING ENDOTHELIAL FUNCTION AND METHODS OF USE THEREOFAugust 2021April 2025Allow4411YesNo
17305713Isolation and Semi-Synthesis of Rufomycin AnalogsJuly 2021October 2025Allow5121YesNo
17364153HYDROGEL-FORMING PEPTIDES, AND METHODS OF USE THEREOFJune 2021March 2024Allow3211YesNo
17312484NOVEL PROTEIN, AND THERAPEUTIC AND COSMETIC USES THEREOFJune 2021September 2024Allow3911YesNo
17334427LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTEMay 2021November 2024Abandon4211NoNo
17303200COMPOSITION OF NUTRITION SUPPLEMENTATION FOR NUTRITIONAL DEFICIENCIES AND METHOD OF USE THEREFOREMay 2021August 2024Abandon3911NoNo
17286851Modified Netrin-1 Peptides and Compositions for CardioprotectionApril 2021February 2026Abandon5751NoNo
17230602METHOD FOR PREVENTION OR TREATMENT OF OBESITY, REDUCING BODY WEIGHT AND/OR FOOD INTAKE, OR INDUCING SATIETY IN A SUBJECTApril 2021February 2023Abandon2201NoNo
17284351GLP-1 RECEPTOR ANTAGONISTSApril 2021March 2025Allow4831YesNo
17222636CHIMERIC CLOTTING FACTORSApril 2021February 2024Abandon3401NoNo
17217285MODIFIED PLASMA CLOTTING FACTOR VIII AND METHOD OF USE THEREOFMarch 2021August 2023Allow2911YesNo
17214189REGULATORY T CELL EPITOPESMarch 2021June 2024Abandon3921YesNo
17209367CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPYMarch 2021November 2023Abandon3210NoNo
17203623MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOFMarch 2021November 2024Abandon4421NoNo
17259904INJECTABLE MICRONIZED HUMAN INSULINJanuary 2021January 2024Abandon3640NoNo
17135877NOVEL LINKER, PREPARATION METHOD, AND APPLICATION THEREOFDecember 2020January 2026Abandon6021YesYes
17103386Composition and Methods of Controllable Co-Coupling Polypeptide Nanoparticle Delivery System for Nucleic Acid TherapeuticsNovember 2020June 2025Abandon5421NoNo
17056340Microneedle Adhesive Patch Based on Hydrogel FormulationNovember 2020December 2024Allow4911YesNo
17067749SYNERGISTIC COMBINATION OF CHEMOTHERAPY AND PEPTIDE FOR TREATING CANCEROctober 2020December 2023Abandon3801NoNo
17045704Proteins for the Treatment of Epithelial Barrier Function DisordersOctober 2020July 2022Allow2111YesNo
17040471PRO-COAGULANT HISTONESSeptember 2020February 2022Abandon1701NoNo
16982115COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE CHECKPOINT INHIBITOR THERAPYSeptember 2020September 2022Abandon2401NoNo
16982114COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GASTROINTESTINAL DAMAGE ASSOCIATED WITH NSAID THERAPYSeptember 2020January 2023Abandon2820NoNo
17002053MINERAL SALT-SULFONIC ACID COMPOSITIONS AND METHODS OF USEAugust 2020May 2022Abandon2010NoNo
16992751TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITYAugust 2020May 2023Abandon3310NoNo
16986790AMYLIN ANALOGUESAugust 2020August 2023Abandon3611NoNo
16925456CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPYJuly 2020June 2021Abandon1110NoNo
16924678ENDOMORPHIN-2, TETRAPEPTIDE DERIVATIVES THEREOF, AND USES THEREOFJuly 2020February 2022Abandon1920YesNo
16769732MODULATORS OF COMPLEMENT ACTIVITYJune 2020September 2025Abandon6041NoNo
16769015Incretin Analogs and Uses ThereofJune 2020April 2023Allow3411YesNo
16763732PACAP STABILIZED PEPTIDEMay 2020February 2025Allow5721YesNo
16850818Combination Therapy for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and DiseasesApril 2020February 2024Abandon4611NoNo
16805370NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENTFebruary 2020August 2021Allow1810YesNo
16638816IMMUNOTHERAPY AGAINST TRANSFERRIN RECEPTOR 1 (TFR1)-TROPIC ARENAVIRUSESFebruary 2020September 2024Abandon5531YesNo
16750742PEPTIDE THERAPIES FOR REDUCTION OF MACULAR THICKENINGJanuary 2020January 2023Allow3610YesNo
16632546ULTRASOUND-ASSISTED SIMULATED DIGESTION METHOD OF MILK PROTEIN ACTIVE PEPTIDE AND APPLICATION THEREOF IN HEALTH FOODSJanuary 2020September 2022Allow3211YesNo
16738792BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCEJanuary 2020January 2022Abandon2520NoNo
16628594COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANESJanuary 2020August 2023Allow4400YesNo
16732545TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITYJanuary 2020October 2022Abandon3410NoNo
16725319METHOD OF TREATING LOW BLOOD PRESSUREDecember 2019December 2023Abandon4821YesNo
16712383CATIONIC ANTIMICROBIAL PEPTIDESDecember 2019April 2022Abandon2820NoNo
16668754PURIFIED THERAPEUTIC NANOPARTICLES AND PREPARATION METHODS THEREOFOctober 2019August 2023Abandon4630YesNo
16606455METHODS OF TREATING GASTROINTESTINAL MOTILITY-RELATED DISORDERS USING VARIANTS AND FUSIONS OF FGF19/FGF21 POLYPEPTIDESOctober 2019August 2022Abandon3401NoNo
16657507MEDICAMENT FOR MITIGATING CONDITIONS AND/OR SUPPRESSING ONSET OF PERIPHERAL NEUROPATHY INDUCED BY ANTI-MALIGNANT TUMOR AGENTOctober 2019May 2022Allow3130YesNo
16566992GLUCAGON ANALOGUESSeptember 2019June 2023Allow4511YesNo
16485190GLP-1R AGONISTS AND USES THEREOFAugust 2019February 2023Allow4230YesNo
16480142COMPOSITIONS AND RELATED METHODS FOR AGRICULTUREJuly 2019October 2025Abandon6041NoNo
16449632MINERAL SALT-SULFONIC ACID COMPOSITIONS AND METHODS OF USEJune 2019May 2020Allow1110NoNo
16448910PEPTIDE-OLIGOUREA CHIMERIC COMPOUNDS AND METHODS OF THEIR USEJune 2019March 2022Abandon3320NoNo
16435350Engineered Cyclic PeptidesJune 2019November 2023Abandon5351YesNo
16466488COMPOSITION FOR SUPPRESSING MUSCULAR ATROPHYJune 2019February 2022Allow3211YesNo
16427493POLYPEPTIDES FOR USE IN SELF-ASSEMBLING PROTEIN NANOSTRUCTURESMay 2019July 2022Allow3820YesNo
16465524FUNCTIONALIZATION OF BIOPOLYMERS WITH GROWTH FACTOR-BINDING PEPTIDESMay 2019December 2024Allow6031YesNo
16348540NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENTMay 2019November 2021Allow3010YesNo
16402612Tricalcium Phosphate Binding Peptides And Uses ThereofMay 2019December 2022Abandon4421NoNo
16389292PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNIIApril 2019July 2023Allow5121YesNo
16340657METHODS AND COMPOSITION FOR DETECTING CAPN5April 2019January 2024Allow5721YesNo
16372692HETEROTANDEM BICYCLIC PEPTIDE COMPLEXESApril 2019February 2022Allow3431YesNo
16337886Methods And Compositions For Noninvasive Detection Of Organ Transplant RejectionMarch 2019October 2024Abandon6041NoNo
16363890SAP AND PEPTIDOMIMETIC COMPOSITIONS FOR REDUCING SYMPTOMS OF INFLAMMATIONMarch 2019December 2022Abandon4521NoNo
16288374CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPYFebruary 2019September 2020Abandon1820NoNo
16324844SILK-DERIVED PROTEIN FOR TREATING INFLAMMATIONFebruary 2019September 2021Allow3121YesNo
16322214GLUTAMINE FOR PRESERVING, IMPROVING OR RESTORING KIDNEY FUNCTIONJanuary 2019March 2025Abandon6040YesYes
16315388STABLE LIQUID FIBRINOGENJanuary 2019August 2025Abandon6041YesNo
16256752INHIBITING TUMOR CELL MIGRATION BY INHIBITION OF KINESIN LIGHT CHAIN 1, VARIANT 1 (KLC1C)January 2019December 2021Allow3411YesNo
16313192ENDOMORPHIN-2, TETRAPEPTIDE DERIVATIVES THEREOF, AND USES THEREOFDecember 2018August 2020Abandon2021NoNo
16312357Modified FibroinDecember 2018November 2023Abandon5931YesNo
16218990TARGETING WITH FIRBRONECTIN TYPE III LIKE DOMAIN MOLECULESDecember 2018January 2023Abandon4941YesNo
16216744PEPTIDE PARTICLE FORMULATIONDecember 2018December 2020Abandon2420NoNo
16302846GLUCAGON-LIKE PEPTIDE-1-T3 CONJUGATESNovember 2018February 2021Abandon2701NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FISCHER, JOSEPH.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
5
Examiner Affirmed
5
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
1.0%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
14
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
14
(100.0%)
Filing Benefit Percentile
0.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner FISCHER, JOSEPH - Prosecution Strategy Guide

Executive Summary

Examiner FISCHER, JOSEPH works in Art Unit 1658 and has examined 176 patent applications in our dataset. With an allowance rate of 40.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner FISCHER, JOSEPH's allowance rate of 40.3% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by FISCHER, JOSEPH receive 2.27 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by FISCHER, JOSEPH is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +51.7% benefit to allowance rate for applications examined by FISCHER, JOSEPH. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 19.0% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 10.5% of cases where such amendments are filed. This entry rate is in the 10% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 28.6% of appeals filed. This is in the 3% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 95.5% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.6% of allowed cases (in the 61% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.8% of allowed cases (in the 73% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.